摘要
目的探讨Crk在乳腺癌中的表达及其临床意义。方法应用免疫组化方法检测Crk在125例乳腺癌和20例乳腺良性肿瘤组织中的表达,分析其与乳腺癌临床病理特征及预后的关系。结果Crk在乳腺癌组织中的阳性表达率为39.2%,明显高于在乳腺良性肿瘤中的表达(χ2=6.447,P=0.011),Crk表达与乳腺癌组织学分级(χ2=4.965,P=0.026)有关,与TNM分期(r=0.258,P=0.004)、淋巴结转移(r=0.261,P=0.004)和HER-2(r=0.287,P=0.021)呈正相关;Crk表达阳性组和阴性组的5年特异生存率分别为38.4%和63.4%,差异有统计学意义(P=0.018)。结论Crk蛋白在乳腺癌组织中表达上调,其高表达提示乳腺癌生物学恶性度较高,预后不良。对乳腺癌患者组织标本进行Crk检测,有助于指导乳腺癌患者的个体化治疗。
Objective To explore the Crk expression in breast cancer and its clinical significance. Methods The expression of Crk was detected in 125 breast cancer tissues and 20 benign tumor tissues by immunohistochemistry and the relationship with clinicopathological parameters and prognosis was analyzed. Results The positive rate of Crk expression in breast cancer was 39.2%,which was significantly higher than that in benign tumor tissues of breast（χ^2=6.447,P=0.011）.Crk expression related to histologic grade （χ^2=4.965,P=0.026）,and correlated positively with TNM stage （r=0.258,P=0.004）,lymph node status（r=0.261,P=0.004） and HER-2 status（r=0.287,P=0.021）.In addition,Kaplan-Meier curves of disease-specific survival analysis showed a significant difference between Crk positive group and negative group （P=0.018）. Conclusions Crk protein expression is up-regulated in primary breast cancer,indicating a more aggressive phenotype and poor prognosis.Crk detection may provide valuable information for risk assessment and identify a subset of patients requiring more aggressive adjuvant therapy.
出处
《实用肿瘤杂志》
CAS
北大核心
2009年第5期446-449,共4页
Journal of Practical Oncology
基金
浙江省自然科学基金资助项目(Y207301)
